A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: Camrelizumab Plus Chemotherapy and Famitinib|DRUG: Camrelizumab Plus Chemotherapy
Sponsor: Fudan University